Morgan Bayer

IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

The FDA fast-tracked BGB-16673 for advanced CLL/SLL, Ticiana Leal, MD, compares lurbinectedin and topotecan for extensive-stage SCLC, and sonrotoclax and zanubrutinib show improved results in early CLL/SLL trials.

T-DXd receives FDA breakthrough therapy designation for HR+/HER2-low breast cancer and real-world data confirms brexu-cel’s efficacy in relapsed/refractory B-cell ALL. A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Apalutamide offers a quicker, deeper PSA response vs enzalutamide in mCSPC and the SENTRY study supports SOC combination therapy for myelofibrosis. We also cover integrative oncology, which has been shown to reduce cancer-related anxiety and depression and we explore vorasidenib’s FDA approval in glioma treatment.

FDA approves afami-cel for advanced synovial sarcoma and dostarlimab is now approved for all advanced endometrial cancers. In addition, buprenorphine offers improved pain management for bone marrow transplant patients, subcutaneous amivantamab reduces AEs, and SRS offers benefits over WBRT for SCLC.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

The FDA’s ODAC mandates phase assessments for NSCLC trials, dendritic cell immunotherapy shows improved survival in pancreatic cancer, and a new blood test for colorectal cancer receives FDA approval. In addition, pembrolizumab plus neoadjuvant chemo proves effective in unresectable HGSC and THIO-cemiplimab combo shows lower toxicity in advanced NSCLC.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

The FDA cleared ADC, ZW191, for difficult-to-treat cancers, immunotherapy showed varied efficacy in angiosarcomas, and the cabozantinib/nivolumab combination demonstrated promising results in RCC. We also cover FDA setbacks for botensilimab/balstilimab in mCRC, and the lackluster effects of nivolumab/tivozanib for RCC.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Amivantamab/lazertinib trumps osimertinib in lung cancer treatment, promising results with nivolumab in dMMR in gynecologic cancers, and Curium’s lutetium-177 submission for SSTR-positive GEP-NETs are featured. Regarding lung cancer, we also cover valuable insights on immunotherapy combinations and breakthrough treatments presented at ASCO.

A handful of positive news highlights new treatments: Orca-T’s superior outcomes in hematologic malignancies, 225Ac-FL-020 receiving fast track for prostate cancer, the addition of glofitamab leading to greater efficacy in DLBCL, and real-world data demonstrating lenvatinib’s effectiveness in RAI-refractory thyroid cancer.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

REGN7075 shows promise in cold tumors, dilutable thiotepa is approved, and patritumab deruxtecan receives a complete response letter for EGFR-mutated NSCLC. We also cover observed predictors for polycythemia vera and fast tract designation for TUB-040 for the treatment of platinum-resistant ovarian cancer.

Switch maintenance therapy with paclitaxel plus ramucirumab consistently prolonged survival regardless of clinical or molecular subgroups in HER2-negative disease controlled, metastatic gastric cancer.

The FDA approved adagrasib with cetuximab for KRAS G12C-mutated CRC and an AI-driven mortality models improve palliative care. We also cover data on datopotamab deruxtecan showing promise in HER2-low breast cancer, zanubrutinib plus venetoclax achieving 100% ORR in high-risk CLL/SLL, and an overview of treatments HER2-targeted treatments highlighting T-DXd in CNS involvement.

Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing various treatment combinations, along with recommendations for first-line systemic therapy.

Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.

Endometrial cancer scores 2 approvals, and PFS benefit is observed with amivantamab/chemotherapy in NSCLC. We also cover T-DXd efficacy in HER2 breast cancer with brain metastasis and the approval of repotrectinib for NTRK-positive solid tumors.

Recommendations on adoptive cell therapy with tumor-infiltrating lymphocytes that address the newly approved therapy lifileucel explore safe administration practices and optimal patient selection based on individual characteristics.

In a prognostic study, an artificial intelligence model significantly outperformed oncologists in predicting short-term mortality, resulting in a 60% positive predictive value vs 34.8%, which involved 57 physicians and 17 advanced practice clinicians.

Delving into the power of ADCs and intriguing data presented at the 2024 ASCO Annual Meeting, including benefits observed with nivolumab-cabozantinib in advanced RCC and the durable responses seen in endometrial cancer with envafolimab-lenvatinib. We also cover data on JNJ-6420 for metastatic CRPC, and the improvements seen with enfortumab vedotin plus pembrolizumab in urothelial cancer.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

In clinical trials, dostarlimab continues to show a 100% CR in dMMR rectal cancer, camrelizumab plus rivoceranib improved survival in untreated uHCC, lorlatinib provided durable PFS in ALK+ lung cancer. We also cover the acknowledged BLA for zolbetuximab and the meaningful PFS achieved with ibrutinib/venetoclax in CLL/SLL.